89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company's common stock to four new employees (the "Inducement Grants") on May 6, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
舊金山，2024 年 5 月 10 日（GLOBE NEWSWIRE）— 專注於開發和商業化治療肝臟和心臟代謝疾病創新療法的臨床階段生物製藥公司89bio, Inc.（“公司” 或 “89bio”）（納斯達克股票代碼：ETNB）今天宣佈，公司董事會薪酬委員會批准向其授予不合格股票期權於2024年5月6日（“授予日期”）向四名新員工共購買48,150股公司普通股（“激勵補助金”）。激勵補助金是根據公司2023年激勵計劃（“計劃”）發放的。根據納斯達克上市規則5635（c）（4），激勵補助金是作爲激勵材料發放給這些在89bio工作的個人的。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
激勵補助金的每股行使價等於89bio普通股在授予日的收盤價。激勵補助金將在四年內歸屬，其中 25% 的股份將在員工入職一週年之際歸屬，此後，其餘股份將分12次等額分季度歸屬，前提是每位員工在適用的歸屬日期之前繼續在89bio工作。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
關於 89bio
89bio是一家臨床階段的生物製藥公司，致力於爲缺乏最佳治療選擇的肝臟和心臟代謝疾病患者開發一流的療法。該公司專注於通過治療代謝功能障礙相關性脂肪肝炎（MASH）和嚴重高甘油三酯血癥（SHTG）的臨床開發，快速推進其主要候選藥物pegozafermin的發展。Pegozafermin 是一種專門設計的、可能是同類最佳的成纖維細胞生長因子 21 (FGF21) 類似物，採用獨特的糖聚合技術，可通過延長半衰期來優化生物活性。該公司總部位於舊金山。欲了解更多信息，請訪問 www.89bio.com 或者關注公司 領英。
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投資者聯繫人：
張安妮
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci 顧問有限公司
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒體聯繫人：
Sheryl Seapy
真正的化學
sseapy@realchemistry.com